Quick Answer
Tempest Therapeutics, Inc. reported Total Revenue of $295.0 thousand for fiscal year 2017.
Tempest Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$26.26M +37.2% |
-$41.84M -41.9% |
-$29.49M +17.4% |
-$35.71M -26.2% |
-$28.30M -47.3% |
-$19.21M +56.9% |
| Diluted EPS | -$6.33 +67.5% |
-$19.50 -920.9% |
-$1.91 +38.2% |
-$3.09 +58.6% |
-$7.47 +81.8% |
-$41.03 |
| Total Assets | $16.93M -59.2% |
$41.49M -19.6% |
$51.60M +12.0% |
$46.09M -37.1% |
$73.24M +220.3% |
$22.86M -69.5% |
| Cash and Equivalents | $7.71M -74.5% |
$30.27M -22.8% |
$39.23M +25.6% |
$31.23M -39.7% |
$51.83M +175.4% |
$18.82M -69.9% |
| Long-Term Debt | — | $0.00 -100.0% |
$6.26M -39.6% |
$10.37M -31.2% |
$15.07M +24603.3% |
$61.0K -63.7% |
| Stockholders Equity | $6.67M -65.1% |
$19.13M -28.5% |
$26.77M +47.8% |
$18.11M -49.9% |
$36.12M +152.5% |
-$68.79M -36.6% |
| R&D Expense | — | — | — | — | — | — |
| Operating Income | -$26.57M +36.8% |
-$42.03M -44.1% |
-$29.16M +15.8% |
-$34.64M -28.4% |
-$26.99M -39.8% |
-$19.30M +57.5% |
| Shares Outstanding | 4.93M +45.7% |
3.38M -84.7% |
22.05M +109.6% |
10.52M +52.2% |
6.91M -63.6% |
19.00M +4.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2018 | $55.0K | -1.8% | -32.1% |
| Revenue (ASC 606) | September 30, 2018 | $55.0K | -1.8% | -32.1% |
| Net Income | September 30, 2025 | -$3.51M | +66.7% | +55.4% |
| Diluted EPS | September 30, 2025 | -$0.79 | +85.2% | +61.8% |
| Total Assets | September 30, 2025 | $17.13M | -49.4% | -30.0% |
| Cash and Equivalents | September 30, 2025 | $7.51M | -66.0% | -47.4% |
| Long-Term Debt | September 30, 2024 | $0.00 | -100.0% | -100.0% |
| Stockholders Equity | September 30, 2025 | $6.35M | -44.6% | -35.1% |
| R&D Expense | September 30, 2018 | $1.68M | -58.2% | -29.8% |
| Operating Income | September 30, 2025 | -$3.60M | +65.9% | +54.8% |
| Shares Outstanding | September 30, 2025 | 4.44M | -83.3% | +0.1% |
- Tempest Therapeutics, Inc. reported Total Revenue of $295.0 thousand for fiscal year 2017.
- Tempest Therapeutics, Inc. showed a decrease of -54.8% in Total Revenue compared to the prior fiscal year.
- Tempest Therapeutics, Inc. reported Net Income of -$26.26 million for fiscal year 2025.
- Tempest Therapeutics, Inc. showed an increase of +37.2% in Net Income compared to the prior fiscal year.
- Tempest Therapeutics, Inc. reported Diluted EPS of $6.33 per share (loss) for fiscal year 2025.
- Tempest Therapeutics, Inc. showed an increase of +67.5% in Diluted EPS compared to the prior fiscal year.
- Tempest Therapeutics, Inc. reported Total Assets of $16.93 million for fiscal year 2025.
- Tempest Therapeutics, Inc. showed a decrease of -59.2% in Total Assets compared to the prior fiscal year.
- Tempest Therapeutics, Inc. reported Cash and Equivalents of $7.71 million for fiscal year 2025.
- Tempest Therapeutics, Inc. showed a decrease of -74.5% in Cash and Equivalents compared to the prior fiscal year.
- Tempest Therapeutics, Inc. reported Long-Term Debt of $0.00 for fiscal year 2024.
- Tempest Therapeutics, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Tempest Therapeutics, Inc. reported Stockholders Equity of $6.67 million for fiscal year 2025.
- Tempest Therapeutics, Inc. showed a decrease of -65.1% in Stockholders Equity compared to the prior fiscal year.
- Tempest Therapeutics, Inc. reported R&D Expense of $18.34 million for fiscal year 2017.
- Tempest Therapeutics, Inc. showed a decrease of -15.3% in R&D Expense compared to the prior fiscal year.
- Tempest Therapeutics, Inc. reported Operating Income of -$26.57 million for fiscal year 2025.
- Tempest Therapeutics, Inc. showed an increase of +36.8% in Operating Income compared to the prior fiscal year.
- Tempest Therapeutics, Inc. reported Shares Outstanding of 4.93 million shares for fiscal year 2025.
- Tempest Therapeutics, Inc. showed an increase of +45.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: